Novartis: FDA approves MS drug Gilenya to treat children
(CercleFinance.com) - The US Food and Drug Administration has approved Swiss drugmaker Novartis' drug Gilenya to treat children and teenagers with relapsing forms of multiple sclerosis, the company said on Monday.
This pediatric indication for children and adolescents between 10 and 18 expands the age range for Gilenya, which was previously approved for patients of at least 18 years old, Novartis said.
While multiple sclerosis is mainly diagnosed in adults, children and teenagers often experience more frequent relapses and brain lesions than adults, the company said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
This pediatric indication for children and adolescents between 10 and 18 expands the age range for Gilenya, which was previously approved for patients of at least 18 years old, Novartis said.
While multiple sclerosis is mainly diagnosed in adults, children and teenagers often experience more frequent relapses and brain lesions than adults, the company said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.